000			02945cam a2200349 a 4500
003			EG-GiCUC
005			20250223032615.0
008			201018s2020 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.10.M.Sc.2020.He.A
100	0		_aHeba Ahmed Abdelgayed Ibrahim
245	1	0	_aAssessment of the expression of IL-27 in patients with psoriasis vulgaris / _cHeba Ahmed Abdelgayed Ibrahim ; Supervised Mohammed Hussein Medhat Elkomy , Olfat Gamil Shaker , Aya Magdi Ibrahim Alorbani
246	1	5	_aقياس مستوى مادة انترليوكين 27 فى مرضى الصدفية
260			_aCairo : _bHeba Ahmed Abdelgayed Ibrahim , _c2020
300			_a117 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Dermatology and Venerology
520			_aBackground: Although it is now considered a prototypic Th1/Th17-mediated disease, several gaps still exist in our understanding of the pathogenesis of psoriasis. IL-27 is a novel cytokine of the IL-12 family. Research on IL-27 uncovered its pleiotropic rolein the differentiation and function of distinct T-cell subsets. Previous studies have proposed that IL-27 may be involved in the complex pathogenesis of psoriasis. Objective: Our aim is tostudy the expression of IL-27 inpatients with psoriasis in comparison to controls, and to assess its relation to clinical disease parameters. Methods: 25 psoriatic patients and 30 age, sex and skin type matched controls were included. Full clinical examination was done and both tissue and serum levels of IL-27 were measured by ELISA. Results:The mean IL-27 levels in both tissue and serum of psoriasis patients were significantly higher when compared to controls (P=<0.001, 0.005 respectively). We also detected a significant negative correlation between the patients{u2019} sera levels of IL-27 and disease severity, expressed in both PASI score and extent of the disease, (P=0.007, 0.002, r=-0.528, -0.600 respectively). Limitations: Small sample size Conclusion: Based on the findings of our study, it can be speculated that IL-27 can serve as a protective cytokine that is upregulated as a counter measure at the early stages of psoriasis initiation, but with increasing disease activity, this cytokine is suppressed; by a yet to be elucidated mechanism, giving way for pro-inflammatory responses to overwhelm and exacerbate the condition
530			_aIssued also as CD
653		4	_aAetiopathogenesis-IL-27
653		4	_aPsoriasis
653		4	_aTh1/17
700	0		_aAya Magdi Ibrahim Alorbani , _eSupervisor
700	0		_aMohammed Hussein Medhat Elkomy , _eSupervisor
700	0		_aOlfat Gamil Shaker , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c78279 _d78279